Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alfuzosin + dutasteride
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Alfuzosin + dutasteride is an oral combination drug consisting of two active pharmaceutical ingredients: **alfuzosin**, an alpha-1 adrenergic receptor blocker, and **dutasteride**, a 5-alpha-reductase inhibitor. This combination is used to treat symptoms of benign prostatic hyperplasia (BPH), a non-cancerous enlargement of the prostate in men. Alfuzosin selectively relaxes smooth muscle in the prostate and bladder neck via antagonism of alpha-1-adrenergic receptors, improving urine flow and relieving lower urinary tract symptoms. Dutasteride inhibits type I and II 5-alpha-reductase isoenzymes, reducing the conversion of testosterone to dihydrotestosterone (DHT), a hormone implicated in the development and progression of prostate enlargement. The dual approach provides both rapid symptom relief (alfuzosin) and reduction in prostate volume and disease progression (dutasteride)[1][2][5].
- Brand names
- Alfugem D
- Other names
- alfuzosin/dutasteridealfuzosin HCl + dutasteridealfuzosin hydrochloride + dutasteride
02
Targets
SRD5A2 (Steroid 5-alpha-reductase type II)ADRA1A (α1A)SRD5A1 (Steroid 5-alpha-reductase type 1)
Beyond the preview
Go deeper on alfuzosin + dutasteride.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alfuzosin + dutasteride.